Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05398796 |
|
Recruitment Status :
Active, not recruiting
First Posted : June 1, 2022
Last Update Posted : April 26, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
Nipah virus (NiV) is transmitted from animals to humans, from humans to humans, and through contaminated food. Infected people may have a cough and trouble breathing. Some people may develop serious symptoms, such as brain inflammation, that can lead to death. There are no drugs or vaccines to treat or prevent NiV infection.
Objective:
To test the safety of an experimental vaccine (mRNA-1215) for NiV. Researchers will also evaluate how participants bodies respond to the vaccine.
Eligibility:
Healthy, nonpregnant adults aged 18 to 60 years.
Design:
Participants will visit the NIH clinic 13 to 15 times over 14 to 16 months.
Participants will get 2 doses of the experimental vaccine during this study at either 1 month or 4 months apart. The vaccine will be given as a shot into the muscle of the upper arm. Participants will stay in the clinic at least 30 minutes after each vaccination.
Participants will be given a diary card and a thermometer. They will record their temperature and any other symptoms for 7 days after each vaccination.
During each follow-up visit, 3 to 14 tubes of blood will be drawn for research.
Participants may undergo an optional procedure called apheresis. A needle will be placed into a vein in each arm. Blood will be removed through one needle. The blood will pass through a machine that separates some of the blood cells. The rest of the blood will return to the body through the other needle.
The study vaccine cannot cause NiV infection.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Nipah Virus Infection | Biological: mRNA -1215 | Phase 1 |
Design:
This Phase I, dose escalation, open label clinical trial is the first study of mRNA-1215 in healthy adults to evaluate the safety, tolerability, and immunogenicity of a Nipah virus (NiV) mRNA vaccine. The hypotheses are that the vaccine will be safe, tolerable, and will elicit an immune response in healthy adults.
Study Product:
mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization. mRNA-1215 was co-developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Disease (NIAID) and ModernaTX, Inc, and manufactured by ModernaTX.
Subjects:
Healthy adults, 18 to 60 years of age.
Plan:
Subjects will be enrolled at the NIH Clinical Center and will receive mRNA-1215 via intramuscular (IM) injection by needle and syringe into the deltoid muscle. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. The mRNA-1215 vaccine dose for Group 4 will be selected based on interim analysis of safety and immunogenicity data from Groups 1-3. Subjects will be evaluated for safety and immune responses through clinical observation and blood collection at specified timepoints throughout the study. The study schema is as follows:
Study Schema
Group Subjects Dose/Route Day 0 Week 4
- 10 25 mcg IM X X
- 10 50 mcg IM X X
- 10 100 mcg IM X X
- 10 10 mcg IM X X
Total **40
**Enrollment up to 50 subjects is permitted in case additional evaluations are required for safety or immunogenicity.
Duration:
Subjects will be evaluated for safety and immune responses throughout the study for 52 weeks following last product administration.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults |
| Actual Study Start Date : | July 11, 2022 |
| Estimated Primary Completion Date : | October 1, 2024 |
| Estimated Study Completion Date : | October 1, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group 1
25 mcg IM
|
Biological: mRNA -1215
mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization. |
|
Experimental: Group 2
50 mcg IM
|
Biological: mRNA -1215
mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization. |
|
Experimental: Group 3
100 mcg IM
|
Biological: mRNA -1215
mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization. |
| Experimental: Group 4 |
Biological: mRNA -1215
mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization. |
- To evaluate the safety and tolerability of a 2-dose vaccine regimen of mRNA-1215 [ Time Frame: Through 52 weeks after last product administration ]X mcg IM of mRNA-1215 to healthy adults; dose will be determined based on evaluation of Groups 1-3.
- To evaluate the safety and tolerability of a 2-dose vaccine regimen of mRNA-1215 [ Time Frame: Through 52 weeks after last product administration ]50 mcg IM of mRNA-1215 to healthy adults
- To evaluate the safety and tolerability of a 2-dose vaccine regimen of mRNA-1215 [ Time Frame: Through 52 weeks after last product administration ]25 mcg IM of mRNA-1215 to healthy adults
- To evaluate the safety and tolerability of a 2-dose vaccine regimen of mRNA-1215 [ Time Frame: Through 52 weeks after last product administration ]100 mcg IM of mRNA-1215 to healthy adults
- To evaluate antibody responses to the mRNA-1215 vaccine [ Time Frame: 2 weeks after last product administration ]The antibody responses to mRNA-1215 will be evaluated at each dose level.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
- INCLUSION CRITERIA:
A subject must meet all of the following criteria:
- Healthy adults between the ages of 18-60 years inclusive.
- Based on history and physical examination, in good general health and without history of any of the conditions listed in the exclusion criteria.
- Able and willing to complete the informed consent process.
- Available for clinic visits for 52 weeks after last product administration.
- Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
-
Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) of 18 to 35 within the 56 days before enrollment.
Laboratory Criteria within 56 days before enrollment:
- White blood cells (WBC) and differential within institutional normal range or accompanied by the site Principal Investigator (PI) or designee approval.
- Total lymphocyte count >= 800 cells/microL.
- Platelets = 125,000 - 500,000 cells/microL.
- Hemoglobin within institutional normal range or accompanied by the PI or designee approval.
- Alanine aminotransferase (ALT) <= 1.25 X institutional upper limit of normal (ULN).
- Aspartate aminotransferase (AST) <= 1.25 X institutional ULN.
- Alkaline phosphatase (ALP) <1.1 X institutional ULN.
- Total bilirubin within institutional normal range or accompanied by the PI or designee approval.
- Serum creatinine <= 1.1 X institutional ULN.
-
Negative for HIV infection by an FDA-approved method of detection
Criteria applicable to women of childbearing potential:
- Negative beta-human chorionic gonadotropin (Beta-HCG) pregnancy test (urine or serum) on the day of enrollment.
- Agrees to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study.
EXCLUSION CRITERIA:
A subject will be excluded if one or more of the following conditions apply:
- Breast-feeding or planning to become pregnant during the study.
- More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment.
- Blood products within 16 weeks prior to enrollment.
- Any vaccine, including COVID-19 vaccines, received within 4 weeks prior to enrollment.
- Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study
- Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule.
- Current anti-TB prophylaxis or therapy.
- Known immediate hypersensitivity to any component of the study product, including polyethylene glycol (PEG).
-
Confirmed past NiV infection, prior residence in (>6 months), or planned travel for any length of time during the study to countries where NiV infection is endemic, eg. Bangladesh, India, Philippines.
Subject has a history of any of the following clinically significant conditions:
- Serious reactions to vaccines that preclude receipt of the study vaccination, including allergic reaction (anaphylaxis, urticaria or allergic reaction requiring medical intervention) to SARS-CoV-2 mRNA vaccines, as determined by the investigator
- History of myocarditis and/or pericarditis
- Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema
- Asthma that is not well controlled
- Diabetes mellitus (type I or II), with the exception of gestational diabetes
- Thyroid disease that is not well controlled
- Idiopathic urticaria within the past year
- Autoimmune disease or immunodeficiency
- Hypertension that is not well controlled
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Malignancy that is active or history of malignancy that is likely to recur during the period of the study
- Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years.
- Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen
- Guillain-Barre Syndrome
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject s ability to give informed consent, including but not limited to clinically significant forms of: infectious diseases, drug or alcohol abuse, autoimmune diseases, psychiatric disorders, or heart disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05398796
| United States, Maryland | |
| National Institutes of Health Clinical Center | |
| Bethesda, Maryland, United States, 20892 | |
| Principal Investigator: | Lesia K Dropulic, M.D. | National Institute of Allergy and Infectious Diseases (NIAID) |
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT05398796 |
| Other Study ID Numbers: |
10000687 000687-I |
| First Posted: | June 1, 2022 Key Record Dates |
| Last Update Posted: | April 26, 2024 |
| Last Verified: | April 24, 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | .Only aggregate data will be shared. |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Rna Vaccine Pandemic Threat First in Human Zoonotic Transmission Protective Immunity |
|
Henipavirus Infections Virus Diseases Infections |
Paramyxoviridae Infections Mononegavirales Infections RNA Virus Infections |